Ovid Therapeutics inks licensing deal with AstraZeneca in epilepsies and other neuropathic conditions
03 Janeiro 2022 - 9:09AM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
Ovid Therapeutics (NASDAQ:OVID)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Ovid Therapeutics (NASDAQ:OVID)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024